Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
2.75
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-3.24 Insider Own23.70% Shs Outstand59.24M Perf Week-14.06%
Market Cap193.88M Forward P/E- EPS next Y-2.29 Insider Trans-0.54% Shs Float53.79M Perf Month-41.86%
Income-192.60M PEG- EPS next Q-0.58 Inst Own74.31% Short Float14.52% Perf Quarter-65.19%
Sales0.00M P/S- EPS this Y28.45% Inst Trans7.14% Short Ratio6.68 Perf Half Y22.22%
Book/sh4.35 P/B0.63 EPS next Y2.81% ROA-53.41% Short Interest7.81M Perf Year-91.40%
Cash/sh4.29 P/C0.64 EPS next 5Y- ROE-56.76% 52W Range1.87 - 40.58 Perf YTD11.34%
Dividend Est.- P/FCF- EPS past 5Y-148.81% ROI-60.65% 52W High-93.22% Beta0.40
Dividend TTM- Quick Ratio22.00 Sales past 5Y0.00% Gross Margin- 52W Low47.45% ATR (14)0.44
Dividend Ex-Date- Current Ratio22.00 EPS Y/Y TTM-42.23% Oper. Margin0.00% RSI (14)30.64 Volatility8.43% 11.42%
Employees80 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price12.12
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q7.64% Payout- Rel Volume0.52 Prev Close2.75
Sales Surprise- EPS Surprise8.98% Sales Q/Q- EarningsMay 09 AMC Avg Volume1.17M Price2.75
SMA20-33.38% SMA50-36.43% SMA200-70.22% Trades Volume605,984 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-12-24Upgrade Wells Fargo Equal Weight → Overweight $7 → $16
Mar-12-24Upgrade Oppenheimer Perform → Outperform $12
Nov-07-23Downgrade Wells Fargo Overweight → Equal Weight $77 → $8
Nov-07-23Downgrade Stifel Buy → Hold $6
Nov-07-23Downgrade Oppenheimer Outperform → Perform
Nov-07-23Downgrade Morgan Stanley Overweight → Equal-Weight $46 → $6
Nov-07-23Downgrade H.C. Wainwright Buy → Neutral
Jun-14-23Resumed Credit Suisse Outperform $63
Mar-21-23Initiated Wells Fargo Overweight $77
Dec-19-22Initiated Goldman Buy $50
Jun-05-24 04:01PM
May-16-24 04:05PM
11:23AM
08:00AM
May-13-24 09:02PM
10:37AM Loading…
10:37AM
May-09-24 08:59PM
04:01PM
May-02-24 04:05PM
Apr-30-24 12:00PM
Apr-17-24 08:45AM
05:45AM
Apr-15-24 01:15PM
Mar-27-24 06:20AM
Mar-20-24 05:45AM
06:02PM Loading…
Mar-18-24 06:02PM
Mar-11-24 07:29AM
07:00AM
Mar-07-24 08:52AM
08:00AM
Mar-06-24 08:00AM
Mar-04-24 08:00AM
Feb-27-24 04:01PM
Feb-22-24 07:00AM
Feb-21-24 04:09PM
Feb-06-24 04:05PM
Dec-23-23 11:01AM
Nov-21-23 04:05PM
Nov-10-23 08:00AM
Nov-09-23 04:01PM
09:35AM Loading…
09:35AM
Nov-07-23 04:20PM
08:47AM
07:00AM
Nov-06-23 04:01PM
Nov-04-23 12:16PM
Oct-11-23 11:37AM
Oct-10-23 04:18PM
12:55PM
07:44AM
Oct-09-23 04:01PM
Oct-07-23 05:00AM
Oct-04-23 11:01PM
Sep-29-23 12:43PM
Sep-08-23 05:07PM
Aug-30-23 04:05PM
Aug-15-23 07:23AM
Aug-10-23 04:01PM
Aug-03-23 04:05PM
Aug-02-23 04:06PM
Jul-12-23 07:22AM
Jul-03-23 02:09PM
Jun-14-23 07:00AM
Jun-07-23 07:00AM
May-31-23 08:00AM
May-12-23 08:57AM
May-11-23 04:01PM
May-04-23 04:05PM
Mar-27-23 07:12AM
Mar-24-23 11:13AM
08:00AM
Mar-23-23 04:01PM
Mar-15-23 04:05PM
Mar-13-23 09:02AM
Mar-11-23 01:21PM
Feb-28-23 08:00AM
Feb-27-23 08:50AM
Feb-13-23 09:55AM
Feb-10-23 08:50AM
Feb-03-23 12:00PM
Jan-26-23 09:55AM
08:00AM
Jan-25-23 08:50AM
Jan-12-23 08:00AM
Jan-05-23 08:00AM
Jan-04-23 09:55AM
Dec-27-22 07:11AM
Dec-22-22 07:26AM
Dec-01-22 04:05PM
Nov-22-22 08:00AM
Nov-11-22 06:35PM
Nov-03-22 04:01PM
Oct-27-22 04:05PM
09:00AM
Oct-24-22 09:55AM
Sep-19-22 09:31AM
08:00AM
Sep-16-22 07:16PM
Sep-14-22 02:01PM
Aug-29-22 04:05PM
Aug-16-22 03:52PM
Aug-15-22 04:05PM
04:01PM
Aug-11-22 04:05PM
Jun-30-22 08:43AM
Jun-29-22 08:00AM
Jun-01-22 08:00AM
May-12-22 04:01PM
May-09-22 08:00AM
May-05-22 04:05PM
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohan RajuCEO AND PRESIDENTJun 10 '24Option Exercise0.2096,77819,3561,675,028Jun 11 04:47 PM
Mohan RajuCEO AND PRESIDENTApr 02 '24Sale5.404,31223,2991,578,250Apr 03 07:32 PM
Krueger Christopher WCHIEF BUSINESS OFFICERApr 02 '24Sale5.401,6518,921284,999Apr 03 07:37 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERApr 02 '24Sale5.401,6518,921264,998Apr 03 07:33 PM
Auster MartinCHIEF FINANCIAL OFFICERApr 02 '24Sale5.401,4057,59224,303Apr 03 07:30 PM
Krueger Christopher WCHIEF BUSINESS OFFICERMar 28 '24Option Exercise0.004,5310286,650Mar 29 06:15 PM
Auster MartinCHIEF FINANCIAL OFFICERMar 28 '24Option Exercise0.004,531025,708Mar 29 06:12 PM
Mohan RajuCEO AND PRESIDENTMar 28 '24Option Exercise0.0011,84301,582,562Mar 29 06:09 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERMar 28 '24Option Exercise0.004,5310266,649Mar 29 06:07 PM
Mohan RajuCEO and PresidentDec 20 '23Sale2.1258,860124,6601,570,719Dec 21 08:10 PM
Nuss JohnChief Scientific OfficerDec 20 '23Sale2.1217,62837,334262,118Dec 21 08:14 PM
Krueger Christopher WChief Business OfficerDec 20 '23Sale2.125,29311,210282,119Dec 21 08:12 PM
Krueger Christopher WChief Business OfficerDec 17 '23Option Exercise0.0010,4790287,412Dec 19 05:25 PM
Nuss JohnChief Scientific OfficerDec 17 '23Option Exercise0.0034,9310279,746Dec 19 05:27 PM
Mohan RajuCEO and PresidentDec 17 '23Option Exercise0.00116,66801,629,579Dec 19 05:30 PM
NSV Partners III LP10% OwnerOct 09 '23Sale30.0349,1521,475,8588,439,635Oct 11 04:21 PM
Subramaniam SomuDirectorOct 09 '23Sale30.0349,1521,475,8588,439,635Oct 11 04:18 PM
Mohan RajuChief Executive OfficerOct 05 '23Option Exercise8.0430,000241,2001,542,911Oct 06 07:16 PM
Mohan RajuChief Executive OfficerOct 05 '23Sale29.1130,000873,2311,512,911Oct 06 07:16 PM
Krueger Christopher WChief Business OfficerOct 03 '23Option Exercise8.0415,000120,600291,548Oct 04 07:33 PM
Nuss JohnChief Scientific OfficerOct 03 '23Option Exercise3.3510,00033,542254,815Oct 04 07:26 PM
Krueger Christopher WChief Business OfficerOct 03 '23Sale29.9815,000449,699276,548Oct 04 07:33 PM
Nuss JohnChief Scientific OfficerOct 03 '23Sale29.9910,000299,933244,815Oct 04 07:26 PM
Subramaniam SomuDirectorSep 18 '23Sale37.8156,6652,142,6348,488,787Sep 20 07:19 PM
NSV Partners III LP10% OwnerSep 18 '23Sale37.8156,6652,142,6348,488,787Sep 20 07:16 PM
Mohan RajuChief Executive OfficerSep 05 '23Option Exercise8.0430,000241,2001,542,911Sep 07 04:25 PM
Krueger Christopher WChief Business OfficerSep 05 '23Option Exercise8.0415,000120,600291,548Sep 07 04:28 PM
Nuss JohnChief Scientific OfficerSep 05 '23Option Exercise0.2010,0002,000254,815Sep 07 04:21 PM
Mohan RajuChief Executive OfficerSep 05 '23Sale32.6130,000978,3431,512,911Sep 07 04:25 PM
Auster MartinChief Financial OfficerSep 05 '23Sale32.6126,472863,33421,177Sep 07 04:31 PM
Krueger Christopher WChief Business OfficerSep 05 '23Sale32.6115,000489,109276,548Sep 07 04:28 PM
Nuss JohnChief Scientific OfficerSep 05 '23Sale32.6010,000325,960244,815Sep 07 04:21 PM
Sandborn William J.See RemarksAug 31 '23Option Exercise14.8511,900176,71560,289Sep 01 04:45 PM
Sandborn William J.See RemarksAug 31 '23Sale33.6411,900400,35448,389Sep 01 04:45 PM
Sandborn William J.See RemarksAug 08 '23Sale32.863,494114,81024,194Aug 08 06:57 PM
Mohan RajuChief Executive OfficerAug 07 '23Option Exercise8.0430,000241,2001,542,911Aug 08 06:54 PM
Mohan RajuChief Executive OfficerAug 07 '23Sale33.5230,0001,005,5701,512,911Aug 08 06:54 PM
Krueger Christopher WChief Business OfficerAug 03 '23Option Exercise8.0415,000120,600291,548Aug 04 06:06 PM
Nuss JohnChief Scientific OfficerAug 03 '23Option Exercise0.2010,0002,000254,815Aug 04 06:08 PM
Krueger Christopher WChief Business OfficerAug 03 '23Sale35.5915,000533,797276,548Aug 04 06:06 PM
Nuss JohnChief Scientific OfficerAug 03 '23Sale35.6010,000355,986244,815Aug 04 06:08 PM
Sandborn William J.See RemarksJul 31 '23Option Exercise14.8511,900176,71560,289Aug 01 04:21 PM
Sandborn William J.See RemarksJul 31 '23Sale37.1611,900442,26148,389Aug 01 04:21 PM
NSV Partners III LP10% OwnerJul 31 '23Sale37.5910,803406,0358,545,452Aug 01 05:43 PM
Subramaniam SomuDirectorJul 31 '23Sale37.5910,803406,0358,545,452Aug 01 05:44 PM
Subramaniam SomuDirectorJul 28 '23Sale37.5361122,9338,556,255Aug 01 05:44 PM
NSV Partners III LP10% OwnerJul 28 '23Sale37.5361122,9338,556,255Aug 01 05:43 PM
Auster MartinChief Financial OfficerJul 25 '23Option Exercise3.4528,00096,60075,649Jul 26 06:51 PM
Auster MartinChief Financial OfficerJul 25 '23Sale35.5428,000995,04447,649Jul 26 06:51 PM
Subramaniam SomuDirectorJul 12 '23Sale37.623,275123,2198,556,866Jul 13 09:25 PM
NSV Partners III LP10% OwnerJul 12 '23Sale37.623,275123,2198,556,866Jul 13 09:26 PM
NSV Partners III LP10% OwnerJul 11 '23Sale37.5428,6461,075,4118,560,141Jul 13 09:26 PM
Subramaniam SomuDirectorJul 11 '23Sale37.5428,6461,075,4118,560,141Jul 13 09:25 PM
Subramaniam SomuDirectorJul 07 '23Sale35.23100,0003,523,0579,552,965Jul 11 09:15 PM
NSV Partners III LP10% OwnerJul 07 '23Sale35.23100,0003,523,0579,552,965Jul 11 09:13 PM
Mohan RajuChief Executive OfficerJul 05 '23Option Exercise8.0429,785239,4711,542,911Jul 05 08:23 PM
Mohan RajuChief Executive OfficerJul 05 '23Sale38.3730,0001,151,2271,512,911Jul 05 08:23 PM
Sandborn William J.See RemarksJul 03 '23Option Exercise14.8511,900176,71560,289Jul 05 08:16 PM
Krueger Christopher WChief Business OfficerJul 03 '23Option Exercise0.7715,00011,538291,548Jul 05 08:18 PM
Nuss JohnChief Scientific OfficerJul 03 '23Option Exercise0.2020,0004,000264,815Jul 05 08:20 PM
NSV Partners III LP10% OwnerJul 03 '23Sale39.00134,0805,229,6989,652,965Jul 06 06:25 PM
Subramaniam SomuDirectorJul 03 '23Sale39.00134,0805,229,6989,652,965Jul 06 06:21 PM
Nuss JohnChief Scientific OfficerJul 03 '23Sale39.5820,000791,637244,815Jul 05 08:20 PM
Krueger Christopher WChief Business OfficerJul 03 '23Sale39.2215,000588,343276,548Jul 05 08:18 PM
Sandborn William J.See RemarksJul 03 '23Sale40.0011,900476,01448,389Jul 05 08:16 PM
Sandborn William J.See RemarksJul 03 '23Sale40.003,487139,48027,688Jul 05 08:16 PM
Sandborn William J.See RemarksJun 23 '23Option Exercise0.2010,7902,15859,179Jun 27 06:01 PM
Sandborn William J.See RemarksJun 23 '23Sale32.7010,790352,84448,389Jun 27 06:01 PM